Physician profile
Stephen C Busby
NPI 1225111362
$1,682.42
in general payments reported to CMS, 2019-2025
23 companies · $45.81 in 2025
The $45.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $219 · 2021: $39.43 · 2022: $165 · 2023: $84.95 · 2024: $20.66 · 2025: $45.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $343.90 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $335.87 | 2019-2021 | |
| Amgen INC. | $131.55 | 2019-2025 | Prolia, Evenity |
| Novo Nordisk INC | $125.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.20 | 2019-2020 | |
| Shire North American Group INC | $74.36 | 2019 | |
| Allergan, INC. | $62.71 | 2019 | |
| Merck Sharp & Dohme LLC | $60.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.48 | 2019-2020 | |
| Exact Sciences Corporation | $50.58 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $42.58 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $38.89 | 2019 | |
| Genentech USA, INC. | $38.33 | 2019-2020 | |
| Pfizer INC. | $31.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.20 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.95 | 2019 | |
| Mylan Specialty L.P. | $26.39 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.06 | 2023 | Gvoke Hypopen |
| Phadia US INC. | $21.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.66 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.10 | 2022 | |
| Nabriva Therapeutics, Plc | $13.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Busby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.